Continuing our Life-Long Commitment to Rare Disease Patients Around the World
As our global community continues to navigate the impact of COVID-19, CENTOGENE remains fully open and operational, underlining our continued commitment to patients globally.
ORDER ON CENTOPORTAL®

Back
Img Alt Text

Transforming Global Genetic Data into Medical Decisions

We are a global leader in rare disease diagnosis and research by transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies

CENTOGENE - Revolutionising Genetic Solutions

Explore how CENTOGENE is revolutionizing genetic solutions for patients worldwide

Know More

Coronavirus Testing With CENTOGENE

Coronavirus Testing With CENTOGENE

Enabling you to get back to normal with our range of SARS-CoV-2 testing solutions for individuals and businesses

Read More

Improved Travel With Coronavirus Testing

The Latest Insights Into COVID-19

Keeping you up to date with the most recent news and scientific developments amid the Coronavirus pandemic

Read More

Our goal: providing precise medical diagnosis of inherited diseases at the earliest possible moment; transforming medical expertise and analytical information into actionable results for physicians, patients, and pharmaceutical partners.

Our commitment: life-long support for our patients and partners - driven by the continuous improvement of our diagnostic quality and therapeutic options for individual patients.

Company Newsletter

Keep up to date with the latest scientific insights and rare disease news
with your monthly digital edition of CentoBrief

Subscribe Now

CAMBRIDGE, Mass., USA und ROSTOCK & BERLIN, Deutschland, 12. Mai 2021

  • CENTOGENE erweitert sein Test-Angebot am Düsseldorfer Flughafen um den...
Weiterlesen

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD)

Weiterlesen

CENTOGENE’s rare disease mutation database offers new features and previously unpublished variants

Weiterlesen

Research leads to diagnosis and treatment options for rare disease patients

Weiterlesen

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare...

Weiterlesen

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 8, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare...

Weiterlesen

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 9, 2021 (GLOBE NEWSWIRE)

  • Rostock International Parkinson's Disease (ROPAD) Study aims to characterize...
Weiterlesen

ERLÄUTERUNG ZUR PRESSEMITTEILUNG: CENTOGENE ENTDECKT BEI DER SEQUENZIERUNG POSITIVER BEFUNDE SELTENE SARS-COV-2 VARIANTE B.1.525 ERSTMALS IN DEUTSCHLAND

wir...

Weiterlesen